JP7097293B2 - ヒトＦｃ受容体に結合する融合タンパク質 - Google Patents

ヒトＦｃ受容体に結合する融合タンパク質 Download PDF

Info

Publication number
JP7097293B2
JP7097293B2 JP2018500473A JP2018500473A JP7097293B2 JP 7097293 B2 JP7097293 B2 JP 7097293B2 JP 2018500473 A JP2018500473 A JP 2018500473A JP 2018500473 A JP2018500473 A JP 2018500473A JP 7097293 B2 JP7097293 B2 JP 7097293B2
Authority
JP
Japan
Prior art keywords
fusion protein
heavy chain
pharmaceutical composition
seq
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018500473A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018519834A5 (enExample
JP2018519834A (ja
Inventor
アンソニー グリフィン、ロバート
ハンフリーズ、デイヴィッド、ポール
ピータース、シャーリー、ジェーン
Original Assignee
ユーシービー バイオファルマ エスアールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユーシービー バイオファルマ エスアールエル filed Critical ユーシービー バイオファルマ エスアールエル
Publication of JP2018519834A publication Critical patent/JP2018519834A/ja
Publication of JP2018519834A5 publication Critical patent/JP2018519834A5/ja
Application granted granted Critical
Publication of JP7097293B2 publication Critical patent/JP7097293B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018500473A 2015-07-06 2016-07-06 ヒトＦｃ受容体に結合する融合タンパク質 Expired - Fee Related JP7097293B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1511787.2 2015-07-06
GBGB1511787.2A GB201511787D0 (en) 2015-07-06 2015-07-06 Proteins
PCT/EP2016/065914 WO2017005767A1 (en) 2015-07-06 2016-07-06 Fusion proteins which bind to human fc receptors

Publications (3)

Publication Number Publication Date
JP2018519834A JP2018519834A (ja) 2018-07-26
JP2018519834A5 JP2018519834A5 (enExample) 2021-10-28
JP7097293B2 true JP7097293B2 (ja) 2022-07-07

Family

ID=54013529

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018500473A Expired - Fee Related JP7097293B2 (ja) 2015-07-06 2016-07-06 ヒトＦｃ受容体に結合する融合タンパク質

Country Status (10)

Country Link
US (1) US20180194856A1 (enExample)
EP (1) EP3319991A1 (enExample)
JP (1) JP7097293B2 (enExample)
CN (1) CN108473571B (enExample)
AU (1) AU2016290523B2 (enExample)
BR (1) BR112017028331A2 (enExample)
CA (1) CA2991363A1 (enExample)
EA (1) EA201890225A1 (enExample)
GB (1) GB201511787D0 (enExample)
WO (1) WO2017005767A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2016139006A (ru) 2014-03-05 2018-04-05 Юсб Биофарма Спрл Мультимерные fc-белки
SI3325011T1 (sl) 2015-07-24 2021-02-26 Gliknik Inc. Fuzijski proteini humanih proteinskih fragmentov za tvorbo pravilnih multimeriziranih imunoglobulin FC sestavkov s povečanim vezanjem komplementa
GB201607979D0 (en) * 2016-05-06 2016-06-22 Liverpool School Tropical Medicine Monomeric proteins and uses thereof
CA3026420A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
SG11201900427PA (en) 2016-07-22 2019-02-27 Gliknik Inc Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced fc receptor binding
IL266988B2 (en) 2016-12-09 2024-11-01 Gliknik Inc Methods of treating inflammatory disorders with multivalent fc compounds
JP7351835B2 (ja) * 2017-12-14 2023-09-27 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 視神経脊髄炎の処置のための組換えＩｇＧ Ｆｃ多量体
EP3765492A1 (en) * 2018-03-16 2021-01-20 Liverpool School of Tropical Medicine Chimeric fc receptor binding proteins and uses thereof
CN115724985A (zh) * 2021-08-27 2023-03-03 三生国健药业（上海）股份有限公司 一种cdc平台抗体

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011073692A1 (en) 2009-12-18 2011-06-23 The University Of Nottingham Proteins, nucleic acid molecules and compositions
WO2014060712A1 (en) 2012-10-17 2014-04-24 Liverpool School Of Tropical Medicine Immunomodulatory proteins
WO2015132365A1 (en) 2014-03-05 2015-09-11 Ucb Biopharma Sprl Multimeric fc proteins
WO2015132364A1 (en) 2014-03-05 2015-09-11 Ucb Biopharma Sprl Multimeric fc proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147326A1 (en) * 1996-06-14 2002-10-10 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
US6475749B1 (en) * 1999-08-11 2002-11-05 The Regents Of The University Of California Rh hybrid antibody
DE10001372A1 (de) * 2000-01-14 2001-08-02 Deutsches Krebsforsch Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen
WO2016139365A1 (en) * 2015-03-05 2016-09-09 Ucb Biopharma Sprl Polymeric fc proteins and methods of screening to alter their functional characteristics

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011073692A1 (en) 2009-12-18 2011-06-23 The University Of Nottingham Proteins, nucleic acid molecules and compositions
WO2014060712A1 (en) 2012-10-17 2014-04-24 Liverpool School Of Tropical Medicine Immunomodulatory proteins
WO2015132365A1 (en) 2014-03-05 2015-09-11 Ucb Biopharma Sprl Multimeric fc proteins
WO2015132364A1 (en) 2014-03-05 2015-09-11 Ucb Biopharma Sprl Multimeric fc proteins
JP2017509335A (ja) 2014-03-05 2017-04-06 ユーシービー バイオファルマ エスピーアールエル 多量体Ｆｃタンパク質
JP2017512063A (ja) 2014-03-05 2017-05-18 ユーシービー バイオファルマ エスピーアールエル 多量体Ｆｃタンパク質

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BRUNKE, C et al.，mAbs，2013年，Vol.5, No.6，pp.936-945
MEKHAIEL, D.N.A. et al.，Sci. Rep.，2011年，Vol.1，Article no.124 (pp.1-11)
MULLER, R. et al.，Proc. Natl. Acad. Sci. USA，2013年，Vol.110, No.25，pp.10183-10188
NAGAOKA, M. and AKAIKE, T.，Protein Eng.，2003年，Vol.16, No.4，pp.243-245
SITIA, R. et al.，Cell，1990年，Vol.60，pp.781-790
SMITH R; ET AL，ADDITION OF A μ-TAILPIECE TO IGG RESULTS IN POLYMERIC ANTIBODIES WITH ENHANCED EFFECTOR 以下備考，THE JOURNAL OF IMMUNOLOGY，米国，THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS，1995年03月01日，VOL:154, NR:5，PAGE(S):2226 - 2236，https://www.ncbi.nlm.nih.gov/pubmed/7868896，FUNCTIONS INCLUDING COMPLEMENT-MEDIATED CYTOLYSIS BY IGG4
SORENSEN V; ET AL，EFFECT OF THE IGM AND IGA SECRETORY TAILPIECES ON POLYMERIZATION AND SECRETION OF IGM AND IGG，THE JOURNAL OF IMMUNOLOGY，米国，THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS，1996年04月15日，VOL:156, NR:8，PAGE(S):2858 - 2865，https://www.ncbi.nlm.nih.gov/pubmed/8609405

Also Published As

Publication number Publication date
CA2991363A1 (en) 2017-01-12
WO2017005767A1 (en) 2017-01-12
GB201511787D0 (en) 2015-08-19
CN108473571A (zh) 2018-08-31
EP3319991A1 (en) 2018-05-16
BR112017028331A2 (pt) 2018-09-11
US20180194856A1 (en) 2018-07-12
AU2016290523B2 (en) 2022-08-25
AU2016290523A1 (en) 2018-01-18
CN108473571B (zh) 2022-04-15
EA201890225A1 (ru) 2018-06-29
JP2018519834A (ja) 2018-07-26

Similar Documents

Publication Publication Date Title
CN114341189A (zh) 全新il-15前药及其应用
EP2697257B1 (en) Fc fusion proteins comprising novel linkers or arrangements
CN110573532B (zh) TGF-β 受体胞外域融合分子及其用途
AU2016290523B2 (en) Fusion proteins which bind to human Fc receptors
US9416182B2 (en) Anti-TNF-anti-IL-17 bispecific antibodies
KR20230029621A (ko) T 세포 억제 단백질을 포함하거나 포함하지 않는 april 및 baff 억제 면역조절 단백질 및 이의 사용 방법
ES2758480T3 (es) Proteína de unión a RGMa y uso de la misma
JP2017513481A (ja) 多量体Ｆｃタンパク質
KR20160130463A (ko) 다량체 Fc 단백질
KR20140027274A (ko) 융합 단백질 TNFR:Fc의 안정한 제약 액체 제제
WO2023045977A1 (zh) 白介素2突变体以及其融合蛋白
US11667704B2 (en) Anti-IL-17 antibody/TNFR ECD fusion protein and use thereof
JP7689116B2 (ja) Ｐｄ１およびｖｅｇｆｒ２二重結合剤
JP2022514187A (ja) ＩＶＩＧの代替のための多量体ハイブリッドＦｃ蛋白質
JP2025535041A (ja) 自己抗体介在疾患の治療における使用のための変異ｔａｃｉ－ｆｃ融合タンパク質
CN107207623A (zh) Fc融合高亲和力IgE受体α链
WO2024046305A1 (zh) 免疫调节剂的筛选和制备方法
WO2024046301A1 (zh) 包含taci多肽的融合蛋白及其用途
CN120435493A (zh) 用于多功能抑制baff、april和新生儿fc受体的taci-fc融合蛋白
JP6529602B2 (ja) 抗ｃｄ２０／抗ｂａｆｆ二重特異性抗体
TWI858383B (zh) 一種ｃｄｃ平臺抗體
JP7734652B2 (ja) 免疫複合体介在性腎臓障害の処置のための組み換えＩｇＧ Ｆｃ多量体
WO2025221933A9 (en) Antibodies and polypeptides comprising variant fc regions
WO2026091090A1 (zh) 结合april的抗体及其用途
WO2023039613A2 (en) Lilrb2-specific monoclonal antibodies and methods of their use

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210907

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20210907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220426

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220602

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220627

R150 Certificate of patent or registration of utility model

Ref document number: 7097293

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees